A Government Accountability Office (GAO) investigation that came to light late last week has revealed that the FDA fails to adequately track and monitor drugs that gain approval through two different expedited processes through which a quarter of all drugs in the country get to market. According to STAT News, the investigators also criticized the FDA for failing to post quarterly reports listing certain potential safety issues that it has identified. Despite a statutory requirement that it do so, last year FDA posted no reports at all in its tracking system. The legislator that requested the GAO review, Representative Rosa DeLauro (D-Conn.), said in a statement: “The GAO report confirms my greatest fear, that FDA lacks fundamental resources and leadership in ensuring that drugs brought quickly to market are truly safe and effective.”
Read further coverage and access the full report here.